Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories.
This report contains market size and forecasts of Anti-Obesity Drugs (Anti-obesity Medication) in global, including the following market information:
- Global Anti-Obesity Drugs (Anti-obesity Medication) Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Anti-Obesity Drugs (Anti-obesity Medication) Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Anti-Obesity Drugs (Anti-obesity Medication) companies in 2021 (%)
The global Anti-Obesity Drugs (Anti-obesity Medication) market was valued at 1876.9 million in 2021 and is projected to reach US$ 5385.2 million by 2028, at a CAGR of 16.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
by Drug Varieties Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anti-Obesity Drugs (Anti-obesity Medication) include Zafgan, Vivus, Shionogi, Sanofi, Rhythm Pharmaceuticals, Pfizer, Orexigen Therapeutics, Novo Nordisk and Norgine, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-Obesity Drugs (Anti-obesity Medication) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-Obesity Drugs (Anti-obesity Medication) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Segment Percentages, by Type, 2021 (%)
- by Drug Varieties
- Prescription Drugs
- OTC Drugs
- by Acting
- Peripherally Acting Anti-obesity Drugs
- Centrally Acting Anti-obesity Drugs
Global Anti-Obesity Drugs (Anti-obesity Medication) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Segment Percentages, by Application, 2021 (%)
- Childhood (0-6)
- Juvenile (7-17)
- Youth (18-40)
- Middle Aged (41-60)
- Elderly (Above 60)
Global Anti-Obesity Drugs (Anti-obesity Medication) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Anti-Obesity Drugs (Anti-obesity Medication) revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Anti-Obesity Drugs (Anti-obesity Medication) revenues share in global market, 2021 (%)
- Key companies Anti-Obesity Drugs (Anti-obesity Medication) sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Anti-Obesity Drugs (Anti-obesity Medication) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Zafgan
- Vivus
- Shionogi
- Sanofi
- Rhythm Pharmaceuticals
- Pfizer
- Orexigen Therapeutics
- Novo Nordisk
- Norgine
- Nalpropion Pharmaceuticals Inc.
- Merck
- GlaxoSmithKline
- F.Hoffmann-La Roche
- Eisai
- Boehringer Ingelheim
- Bayer AG
- AstraZeneca
- Arena Pharmaceuticals
- Amylin
- Alizyme
